**Supplementary table 1.** Cox proportional–hazard analysis for composite primary outcome

<table>
<thead>
<tr>
<th>Variable</th>
<th>Model 1</th>
<th></th>
<th>Model 2</th>
<th></th>
<th>Model 3</th>
<th></th>
<th>Model 4</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>P</td>
<td>HR</td>
<td>P</td>
<td>HR</td>
<td>P</td>
<td>HR</td>
<td>P</td>
</tr>
<tr>
<td>Treatment (AST-120)*</td>
<td>1.111</td>
<td>0.460</td>
<td>1.106</td>
<td>0.480</td>
<td>1.098</td>
<td>0.509</td>
<td>1.145</td>
<td>0.342</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>0.989</td>
<td>0.037</td>
<td>0.989</td>
<td>0.038</td>
<td>0.985</td>
<td>0.004</td>
<td>0.970</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Gender (female)†</td>
<td>0.913</td>
<td>0.548</td>
<td>0.907</td>
<td>0.520</td>
<td>0.758</td>
<td>0.072</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CKD cause (diabetic nephropathy)‡</td>
<td>1.741</td>
<td>&lt;0.001</td>
<td>1.892</td>
<td>&lt; 0.001</td>
<td>1.892</td>
<td>&lt; 0.001</td>
<td>3.163</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>CKD stage (4)§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CKD, chronic kidney disease; HR, hazard ratio. Model 1, treatment arm and age; model 2, + gender; model 3, + CKD cause; model 4, + CKD stage.

Reference: *control, †male, ‡non-diabetic nephropathy, §CKD stage 3.

**Supplementary figure 1.** The slope of 1/serum creatinine (SCr) over time.